【佳学基因检测】肿瘤内异质性对治疗分层的影响

千万不要做基因检测合理吗

挖掘记录《J Pathol》在 2014 Jan;232(2):264-73发表了一篇题目为《肿瘤内异质性对治疗分层的影响》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Andrew Crockford, Mariam Jamal-Hanjani, James Hicks, Charles Swanton等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

瘤内异质性,源自患者的异种移植模型,个性化医疗。

肿瘤靶向治疗基因检测临床应用结果

尽管癌症的诊断和治疗取得了进展，但大多数晚期转移性实体瘤仍然无法治好。个体肿瘤内的差异基因表达、体细胞突变状态、肿瘤特异性遗传特征和微环境选择压力对指导治疗干预的预测分析的成功具有影响。在这篇综述中，我们讨论了遗传和表型异质性的证据及其对临床决策的潜在影响。我们强调了可以改进的研究领域，以便更好地对患者治疗进行分层。我们还讨论了患者衍生的肿瘤反应模型的预测潜力，包括肿瘤内异质性背景下的异种移植和基于细胞系的系统。

肿瘤发生与反复转移国际数据库描述：

Despite advances in the diagnosis and treatment of cancer, the majority of advanced metastatic solid tumours remain incurable. Differential gene expression, somatic mutational status, tumour-specific genetic signatures and micro-environmental selection pressures within individual tumours have implications for the success of predictive assays to guide therapeutic intervention. In this review we discuss the evidence for genetic and phenotypic heterogeneity and its potential implications for clinical decision making. We highlight areas of research that could be improved in order to better stratify patient treatment. We also discuss the predictive potential of patient-derived models of tumour response, including xenograft and cell line-based systems within the context of intratumour heterogeneity.